Analyst Ratings for Myriad Genetics (MYGN)
MYGN Rating Summary
MYGN Price Target Summary
- Highest: $10.00 (Craig-Hallum)
- Lowest: $2.00 (Piper Sandler)
- Average: $4.01
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$4.01 (-5.1%)
* Over Last 12-Mos
Rating Score: 2 / 10
Percentile Rank: 15%
Avg. $ Target:
$4.01 (-5.1%)
* Over Last 12-Mos
Rating Score: 2 / 10
Percentile Rank: 15%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/9/2026 | UBS | Douglas Schenkel | New Coverage | Neutral (N/A) |
3.60 (N/A) |
3.18 (4.23) |
33.02% | Details |
| 9/1/2026 | Piper Sandler | Dave Westenberg | Downgrade | Underweight (Neutral) |
2.00 (5.45) |
3.16 (4.23) |
33.86% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
